Day 1 Coverage, Thursday May 18

Last Updated: Friday, 12-May-2017 13:15:00 EDT

Town Hall Session - Back to the Future: Clinical Experience with and Access to Lipid-Lowering Agents of the Past, Present, and Future

Joyce Ross

Joyce L. Ross, MSN, ANP, CRNP, CLS, FNLA

President, National Lipid Association
Program Chair
University of Pennsylvania Health System- Retired
Philadelphia, PA


Dave L. Dixon, PharmD, BCPS, CDE, AACC, FNLA

Dave L. Dixon, PharmD, BCPS, CDE, AACC, FNLA

Planning Committee Member
Associate Professor, Ambulatory Care
Vice-Chair of Clinical Services
Department of Pharmacotherapy and Outcomes Science
Virginia Commonwealth University
School of Pharmacy
Richmond, VA


Joseph J. Saseen, PharmD, CLS, FNLA

Joseph J. Saseen, PharmD, CLS, FNLA

Clinical Pharmacy & Family Medicine
University of Colorado Denver
Anschutz Medical Campus
Aurora, CO


Dean A. Bramlet, MD, FNL

Dean A. Bramlet, MD, FNLA

Assistant Consulting Professor of Medicine
Duke University
Medical Director, Cardiovascular Diagnostic Center
The Heart & Lipid Institute of Florida
St. Petersburg, FL
Diplomate, American Board of Clinical Lipidology


Daniel J. Rader, MD, FNLA

Daniel J. Rader, MD, FNLA

Seymour Gray Professor of Molecular Medicine
Chair, Department of Genetics
Chief, Division of Translational
 Medicine and Human Genetics
Department of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology


This Town Hall Session was an exciting kick-off to the NLA’s Annual Scientific Sessions. Co-chaired by NLA President Joyce Ross, and Dr. Dixon, the faculty reviewed the history of lipid lowering therapy and projected what is still to come. To start this session, Dr. Saseen reviewed the “PAST” clinical experiences with lipid-lowering drug therapy. He covered the history of statin therapy by focusing on landmark statin trials that have influenced lipid management. In contrast, select evidence using nonstatin therapy was included. Dr. Bramlet covered the “PRESENT” with regard to lipid-lowering drug therapy. He reviewed newly released outcomes data with PCSK9 inhibitors and identify how they are changing the landscape of lipid management. The role of omega-3 fatty acids was included and a discussion on how to use these medications to treat patient populations without clear outcomes data in patients with triglyceride values < 500 mg/dL. This session concluded with Dr. Radar identifying “FUTURE” targets of emerging therapy. There are exciting potential medications that modify Lp(a), ApoC3 and triglyceride-rich lipoproteins.

Stay tuned for more details on our CME/CE digital enduring activity launching on and
Enduring webcast in production with